ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Following the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise its licence option until Aelis has submitted a final data analysis.
Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.
Danish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many properties afforded by protein disorder.
Swedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology in Switzerland.
The extent to which vested interests can delay innovation can currently be seen in the introduction of screening for the dominantly inherited disease familial hypercholesterolaemia, the benefits of which have already been proven in the UK and the Netherlands.
A brand-new AI analysis of 1,500 climate policies across 41 countries between 1998 and 2022 reveals that only 4% achieved significant emission reductions.
Swiss mitophagy specialist Vandria SA has booted its CHF18m Series A financing from December 2023 by further CHF10.3m to push its lead VNA-318 to Phase Ib testing.
Danish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.
German biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved meds.
Good news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.